Drug Profile
Research programme: chelating agents - National Resilience
Alternative Names: Diethylenetriaminepentaacetate oral; DTPA oral; Pentetic acid oralLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Nanotherapeutics
- Developer National Resilience
- Class Antidotes; Polyamines; Radioprotectives
- Mechanism of Action Chelating agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Radiation injuries
Most Recent Events
- 02 Oct 2017 Nanotherapeutics is now called Ology Bioservices
- 16 Jul 2016 No recent reports of development identified for research development in Radiation-injuries in USA (PO)
- 29 Sep 2011 Early research in Radiation injuries in USA (PO)